New Pittsburgh Courier

October is Breast Cancer Awareness Month

As National Breast Cancer Awareness Month begins, the American Cancer Society says progress against the disease should not obscure the significant challenges remaining.
While overall rates of breast cancer in black and white women are about the same, black women are 20-40 percent more likely to die from breast cancer. The reason for this disparity is likely due to several factors, including genetics, the biology of the cancer, and differences in healthcare. Because black women have higher breast cancer mortality rates than white women, the American College of Radiology and the Society of Breast Imaging have recommended that black women be added to groups considered at high risk for breast cancer. This is the first time black women have been classified as a high-risk group.
The recommendations were published in the March 2018 issue of the Journal of the American College of Radiology.
The Facts: Thanks to largely stable incidence rates, improved treatment, and earlier detection through screening and increased awareness, a woman’s risk of dying of breast cancer dropped 39 percent between the late 1980s and 2015, translating into more than 300,000 breast cancer deaths avoided during that time.
However, despite that progress, breast cancer remains the second-leading cause of cancer death in women, second only to lung cancer. There is still a large racial gap in mortality, with African-American women having higher death rates compared to whites, even as incidence rates are similar. There is still much be done.
The American Cancer Society’s estimates for breast cancer in the United States for
2018 are:

At this time, there are more than 3.1 million people with a history of breast cancer in the United States – including women still being treated and those who have completed treatment.
Risk factors:

What the American Cancer Society is Doing
The ACS currently funds 155 multi-year grants focused on breast cancer totaling $60.2 million. The organization has played a key role in many of the advances against breast cancer, including funding early work that eventually led to the development of tamoxifen and Herceptin.
To learn more about ACS CAN’s advocacy work and to help make fighting breast cancer a priority in your community, visit acscan.org/makingstrides.

About Post Author